Advanced search for publications
Enter your keywords
Budget impact of paracetamol 250mg/5ml oral suspension
The purpose of this bulletin is to highlight the increase in cost of paracetamol 250mg/5ml oral suspensions since May 2022. It considers the potential savings that could be achieved through cost-effective paracetamol suspension prescribing across the ICSs in the North East & Yorkshire region and Greater Manchester.
Budget impact of emollient bath and shower preparations
The purpose of this bulletin is to promote cost effective prescribing by highlighting the lack of evidence on the efficacy of emollient bath and shower preparations for the management of atopic eczema, in line with updated NICE guidance. It considers the potential savings that could be achieved with reduced prescribing of these products across the […]
Sustainability: Environmental impact of inhaler disposal
The NHS Long-Term Plan sets out a commitment to reduce NHS carbon emissions by 51% by 2025, and ultimately to become the world’s first Net-Zero health service. Good-quality data comparing the environmental impact of different types of inhalers is essential if patients and prescribers are to make informed decisions about their choice of inhalers in […]
Budget impact of acetylcysteine vs carbocisteine
The purpose of this bulletin is to highlight the difference in cost between acetylcysteine and carbocisteine when used as mucolytics, and to raise awareness of savings which could be achieved within ICBs. The bulletin considers the potential budget impact to primary care prescribing budgets based on current prescribing of carbocisteine across the ICSs in the […]
Budget impact of promethazine prescribing
The purpose of this bulletin is to highlight the rapid NHS price increase of promethazine hydrochloride tablets since July 2022, and to raise awareness of the impact the price increase is having on ICB prescribing budgets. Potential alternative options are outlined, to reduce prescribing costs. The bulletin considers the potential budget impact to primary care […]
Budget impact of methylphenidate modified release tablet choice
The purpose of this bulletin is to highlight the difference in cost between bioequivalent methylphenidate modified release (MR) tablets. It considers the budget impact of MR tablet choice and shows the yearly primary care spend on all methylphenidate XL tablets, and the proportion of this spend on each of the available brands.
NICE TA875; Semaglutide for managing obesity: A briefing for ICSs
In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice […]
Budget impact of metformin 1g immediate release tablet prescribing
The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g […]
Atrial Fibrillation [NICE NG196]: Financial and commissioning impact
In April 2021, NICE published a new guideline NG196 – Atrial fibrillation: diagnosis and management which updates and replaces NICE CG180 (2014). There are a number of new recommendations, which are likely to have both a significant financial impact and potentially affect the way anticoagulation monitoring is managed. This bulletin aims to raise awareness of […]
Impact of Priadel Price Change on CCG Prescribing Budgets
This bulletin aims to raise awareness of the NHS price increase for Priadel® (lithium carbonate) tablets as of November 2020 and the resulting cost impact to primary care. While discussions between the DHSC and the manufacturer of Priadel have prevented its discontinuation from the UK market at this stage, the renegotiated price in November 2020 […]